News & Updates
Showing Respirology articles
Showing

CATALYST sparks signals favouring namilumab for COVID-19
In the phase II proof-of-concept CATALYST trial comparing the GM-CSF* inhibitor namilumab and the TNF** inhibitor infliximab against usual care (UC), namilumab, but not infliximab, demonstrated signals for reducing inflammation in hospitalized patients with COVID-19 pneumonia.

Fluvoxamine may prevent COVID-19 hospitalization
Treatment with the selective serotonin reuptake inhibitor fluvoxamine may prevent hospitalization in outpatients presenting with symptoms of COVID-19 who have a high risk for disease progression, according to results of the TOGETHER trial.

SARS-CoV-2 pneumonia more deadly than bacteraemic pneumococcal pneumonia
Bacteraemic pneumococcal community-acquired pneumonia is associated with higher disease severity and frequent intensive care unit admission, as reported in a study. However, SARS-CoV-2-related pneumonia poses a greater mortality risk.






